Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Apple Turns 50: From Garage Startup to AI Crossroads 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
ALBANY, N.Y., Dec. 20, 2016 -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2017 second quarter ended November 30, 2016, on Friday, January 6, 2017, before the open of the U.S. financial markets.
Management will host a conference call beginning at 8:00am E.T. on January 6 to discuss the results and to answer questions. To participate in the live call by telephone, please call 888-461-2031 and reference the Conference ID: 2977550.
A live webcast and subsequent archived replay of the conference call may be accessed via the investor relations section of the Company's website under "Events & Presentations" at investors.angiodynamics.com/events. To listen to the live webcast, please go to the website 15-minutes prior to its start to register, download and install the necessary audio software.
About AngioDynamics
AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. More information is available at AngioDynamics.com.
Trademarks
AngioDynamics and the AngioDynamics logo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.
Company Contact: AngioDynamics Inc. Caitlin Stefanik (518) 795-1418 [email protected] Investor Relations Contacts: FTI Consulting Jim Polson (312) 553-6730 [email protected], Kotaro Yoshida (212) 850-5690 [email protected] Media Contact: FTI Consulting Kimberly Ha (212) 850-5612 [email protected]
